{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:26:37Z","timestamp":1787955997430,"version":"build-2784847793"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Massachusetts Amherst School of Public Health and Health Sciences","award":["Dean's PhD Summer Dissertation"],"award-info":[{"award-number":["Dean's PhD Summer Dissertation"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parents of children with rare diseases often face uncertainty about diagnosis, treatment, and costs associated with healthcare for their child. Health insurance status impacts each of these areas, but no U.S. study has explored parents\u2019 perceptions of the health insurance impacts on their child\u2019s care. This study aimed to qualitatively explore how these parents navigate the complex health insurance system for their children and their experiences in doing so.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Semi-structured interviews were conducted with parents of children with metachromatic leukodystrophy (MLD) and spinal muscular atrophy (SMA), chosen for specific disease characteristics and orphan drug status. Participants were recruited via e-mail through patient advocacy organizations between September and December 2018. Interviews were conducted via Skype, were recorded, and professionally transcribed. Modified grounded theory was utilized as a methodology to analyze transcripts in an iterative process to determine themes and sub-themes based on participant described experiences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Major themes and subthemes that emerged across the 15 interviews included: (1) difficulties obtaining secondary insurance based on state eligibility criteria; (2) difficulty accessing needed healthcare services; and (3) need for repeated interactions with insurance representatives. The absence of clearly documented or widely recognized clinical guidelines exacerbated the difficulty accessing care identified as necessary by their healthcare team, such as therapy and equipment. An explanatory model for parent\u2019s experiences was developed from the themes and subthemes. The model includes the cyclical nature of interacting with insurance for redundant reauthorizations and the outside support and financial assistance that is often necessary to address their child\u2019s healthcare needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>With complex health conditions, small setbacks can become costly and disruptive to the health of the child and the life of the family. This study suggests that patients with rare diseases may benefit from time limits for processing coverage decisions, increasing transparency in the claims and preauthorization processes, and more expansive authorizations for on-going needs. Additional studies are needed to understand the full scope of barriers and to inform policies that can facilitate better access for families living with rare diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01943-w","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T07:02:58Z","timestamp":1626332578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Navigating the U.S. health insurance landscape for children with rare diseases: a qualitative study of parents\u2019 experiences"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8358-1538","authenticated-orcid":false,"given":"Tai L. S.","family":"Pasquini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Whitehill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"1943_CR1","unstructured":"Genetic and Rare Diseases Information Center (GARD), National Center for Advancing Translational Sciences. Genetic and Rare Diseases Information Center (GARD) \u2013 an NCATS Program [Internet]. NIH.gov. [cited 2017 Jan 13]. https:\/\/rarediseases.info.nih.gov\/"},{"key":"1943_CR2","unstructured":"Orphan Drug Act [Internet]. Federal Food, Drug, and Cosmetic Act, 97\u2013414 1983. https:\/\/www.ecfr.gov\/cgi-bin\/text-idx?c=ecfr&SID=51cf70689d51f0ea4147c0a8ac649321&rgn=div5&view=text&node=21:5.0.1.1.6&idno=21"},{"key":"1943_CR3","unstructured":"National Organization for Rare Disorders (NORD) [Internet]. NORD (National Organization for Rare Disorders). [cited 2017 Apr 19]. https:\/\/rarediseases.org\/"},{"issue":"1","key":"1943_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12913-018-2872-9","volume":"18","author":"A Babac","year":"2018","unstructured":"Babac A, Frank M, Pauer F, Litzkendorf S, Rosenfeldt D, L\u00fchrs V, et al. Telephone health services in the field of rare diseases: a qualitative interview study examining the needs of patients, relatives, and health care professionals in Germany. BMC Health Serv Res. 2018;18(1):99.","journal-title":"BMC Health Serv Res."},{"key":"1943_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2147\/JMDH.S113898","volume":"9","author":"LJ Pelentsov","year":"2016","unstructured":"Pelentsov LJ, Fielder AL, Laws TA, Esterman AJ. Development of the parental needs scale for rare diseases: a tool for measuring the supportive care needs of parents caring for a child with a rare disease. J Multidiscip Healthc. 2016;9:425\u201333.","journal-title":"J Multidiscip Healthc"},{"issue":"17","key":"1943_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12875-016-0488-x","volume":"21","author":"LJ Pelentsov","year":"2016","unstructured":"Pelentsov LJ, Fielder AL, Laws TA, Esterman AJ. The supportive care needs of parents with a child with a rare disease: results of an online survey. BMC Fam Pract. 2016;21(17):88.","journal-title":"BMC Fam Pract"},{"key":"1943_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-90-481-9485-8_14","volume":"686","author":"A Kole","year":"2010","unstructured":"Kole A, Faurisson F. Rare diseases social epidemiology: analysis of inequalities. Adv Exp Med Biol. 2010;686:223\u201350.","journal-title":"Adv Exp Med Biol"},{"key":"1943_CR8","unstructured":"Report of The National Commission on Orphan Diseases [Internet]. 1989 Feb [cited 2017 Mar 31]. https:\/\/rarediseases.info.nih.gov\/files\/report_of_the_national_commission_on_orphan_diseases_february_1989.pdf"},{"key":"1943_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-90-481-9485-8_1","volume":"686","author":"SC Groft","year":"2010","unstructured":"Groft SC, de la Paz MP. Rare diseases - avoiding misperceptions and establishing realities: the need for reliable epidemiological data. Adv Exp Med Biol. 2010;686:3\u201314.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1943_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13023-016-0521-0","volume":"11","author":"S Somanadhan","year":"2016","unstructured":"Somanadhan S, Larkin PJ. Parents\u2019 experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS). Orphanet J Rare Dis. 2016;11(1):138.","journal-title":"Orphanet J Rare Dis."},{"key":"1943_CR11","doi-asserted-by":"crossref","unstructured":"Palacios-Ce\u00f1a D, Famoso-P\u00e9rez P, Salom-Moreno J, Carrasco-Garrido P, P\u00e9rez-Corrales J, Paras-Bravo P, et al. \u201cLiving an Obstacle Course\u201d: A Qualitative Study Examining the Experiences of Caregivers of Children with Rett Syndrome. Int J Environ Res Public Health. 2018 25;16(1).","DOI":"10.3390\/ijerph16010041"},{"key":"1943_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.seizure.2018.12.018","volume":"65","author":"L Lagae","year":"2019","unstructured":"Lagae L, Irwin J, Gibson E, Battersby A. Caregiver impact and health service use in high and low severity Dravet syndrome: a multinational cohort study. Seizure. 2019;65:72\u20139.","journal-title":"Seizure"},{"issue":"1","key":"1943_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1744-6155.2008.00129.x","volume":"13","author":"AM Gallo","year":"2008","unstructured":"Gallo AM, Hadley EK, Angst DB, Knafl KA, Smith CAM. Parents\u2019 concerns about issues related to their children\u2019s genetic conditions. J Spec Pediatr Nurs. 2008;13(1):4\u201314.","journal-title":"J Spec Pediatr Nurs"},{"issue":"3","key":"1943_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pedn.2015.11.009","volume":"31","author":"K Curtis","year":"2016","unstructured":"Curtis K, Foster K, Mitchell R, Van C. Models of care delivery for families of critically ill children: an integrative review of international literature. J Pediatr Nurs. 2016;31(3):330\u201341.","journal-title":"J Pediatr Nurs"},{"key":"1943_CR15","doi-asserted-by":"crossref","unstructured":"Baumbusch J, Mayer S, Sloan-Yip I. Alone in a crowd? Parents of children with rare diseases\u2019 experiences of navigating the healthcare system. J Genet Couns. 2018 Aug 21;","DOI":"10.1007\/s10897-018-0294-9"},{"issue":"1","key":"1943_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cch.12628","volume":"45","author":"G Currie","year":"2019","unstructured":"Currie G, Szabo J. \u201cIt is like a jungle gym, and everything is under construction\u201d: the parent\u2019s perspective of caring for a child with a rare disease. Child Care Health Dev. 2019;45(1):96\u2013103.","journal-title":"Child Care Health Dev"},{"key":"1943_CR17","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics Council on Children with Disabilities. Care coordination in the medical home: integrating health and related systems of care for children with special health care needs. Pediatrics. 2005;116(5):1238\u201344.","DOI":"10.1542\/peds.2005-2070"},{"issue":"3","key":"1943_CR18","first-page":"208","volume":"9","author":"LA Aday","year":"1974","unstructured":"Aday LA, Andersen R. A framework for the study of access to medical care. Health Serv Res. 1974;9(3):208\u201320.","journal-title":"Health Serv Res"},{"key":"1943_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1475-9276-12-18","volume":"12","author":"J-F Levesque","year":"2013","unstructured":"Levesque J-F, Harris MF, Russell G. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. Int J Equity Health. 2013;12:18.","journal-title":"Int J Equity Health"},{"issue":"5","key":"1943_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.7326\/0003-4819-129-5-199809010-00012","volume":"129","author":"DP Andrulis","year":"1998","unstructured":"Andrulis DP. Access to care is the centerpiece in the elimination of socioeconomic disparities in health. Ann Intern Med. 1998;129(5):412\u20136.","journal-title":"Ann Intern Med"},{"key":"1943_CR21","unstructured":"Committee on Geographic Variation in Health Care Spending and Promotion of High-Value Care, Board on Health Care Services, Institute of Medicine. Variation in Health Care Spending: Target Decision Making, Not Geography [Internet]. Newhouse JP, Garber AM, Graham RP, McCoy MA, Mancher M, Kibria A, editors. Washington (DC): National Academies Press (US); 2013. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK201647\/"},{"key":"1943_CR22","unstructured":"Health Insurance Coverage of the Total Population [Internet]. The Henry J. Kaiser Family Foundation. 2017 [cited 2017 Sep 22]. http:\/\/www.kff.org\/other\/state-indicator\/total-population\/"},{"key":"1943_CR23","unstructured":"Centers for Medicare & Medicaid Services. CMS Fast Facts Overview [Internet]. CMS.gov. 2017 [cited 2017 Sep 22]. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/CMS-Fast-Facts\/index.html"},{"key":"1943_CR24","unstructured":"September 2020 Medicaid & CHIP Enrollment Data Highlights | Medicaid [Internet]. [cited 2021 Mar 10]. https:\/\/www.medicaid.gov\/medicaid\/program-information\/medicaid-and-chip-enrollment-data\/report-highlights\/index.html"},{"key":"1943_CR25","doi-asserted-by":"crossref","unstructured":"Mays GP, Claxton G, White J. Managed care rebound? Recent changes in health plans\u2019 cost containment strategies. Health Aff Proj Hope. 2004;Suppl Web Exclusives:W4\u2013427\u201336.","DOI":"10.1377\/hlthaff.W4.427"},{"issue":"5","key":"1943_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jama.2016.9797","volume":"316","author":"B Obama","year":"2016","unstructured":"Obama B. United States health care reform: progress to date and next steps. JAMA. 2016 Aug 2;316(5):525\u201332.","journal-title":"JAMA"},{"issue":"5","key":"1943_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jama.2016.9876","volume":"316","author":"PR Orszag","year":"2016","unstructured":"Orszag PR. US health care reform: cost containment and improvement in quality. JAMA. 2016 Aug 2;316(5):493\u20135.","journal-title":"JAMA"},{"issue":"3","key":"1943_CR28","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/j.pedn.2015.10.022","volume":"31","author":"LJ Pelentsov","year":"2016","unstructured":"Pelentsov LJ, Fielder AL, Esterman AJ. The Supportive Care Needs of Parents With a Child With a Rare Disease: A Qualitative Descriptive Study. J Pediatr Nurs. 2016 Jun;31(3):e207-218.","journal-title":"J Pediatr Nurs"},{"key":"1943_CR29","first-page":"1","volume":"26","author":"MK Kuester","year":"2018","unstructured":"Kuester MK, Jackson EA, Runyan BM, Pezalla EJ, Nussbaum SR. The effect of a pediatric rare disease on subscriber retention rates for commercial health insurers in the United States. J Manag Care Spec Pharm. 2018 Sep;26:1\u20139.","journal-title":"J Manag Care Spec Pharm"},{"key":"1943_CR30","unstructured":"Burden of Rare Disease Study [Internet]. EveryLife Foundation for Rare Diseases. [cited 2021 Mar 9]. https:\/\/everylifefoundation.org\/burden-study\/"},{"key":"1943_CR31","unstructured":"U.S. Food & Drug Administration. Search Orphan Drug Designations and Approvals [Internet]. [cited 2017 Mar 31]. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/index.cfm"},{"issue":"3","key":"1943_CR32","doi-asserted-by":"publisher","first-page":"A4","DOI":"10.1016\/j.jval.2016.03.040","volume":"19","author":"S Alhawwashi","year":"2016","unstructured":"Alhawwashi S, Seoane-Vazquez E, Eguale T, Rodriguez-Monguio R. Prices of drugs for chronic use with orphan designation in the United States (1983\u20132014). Value Health. 2016 May 1;19(3):A4.","journal-title":"Value Health"},{"key":"1943_CR33","unstructured":"American Health Insurance Plans (AHIP). Orphan Drug Utilization and Pricing Patterns (2012\u20132014) [Internet]. Washington, DC; 2016 Oct [cited 2017 Sep 22]. https:\/\/www.ahip.org\/wp-content\/uploads\/2016\/10\/OrphanDrug_DataBrief_10.21.16.pdf"},{"issue":"6","key":"1943_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"17","author":"S Simoens","year":"2011","unstructured":"Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011 Jun;17(6):42.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1943_CR35","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1377\/hlthaff.2016.0030","volume":"35","author":"V Divino","year":"2016","unstructured":"Divino V, DeKoven M, Kleinrock M, Wade RL, Kaura S. Orphan drug expenditures in the United States: a historical and prospective analysis, 2007\u201318. Health Aff Proj Hope. 2016 Sep 1;35(9):1588\u201394.","journal-title":"Health Aff Proj Hope"},{"issue":"10","key":"1943_CR36","first-page":"997","volume":"20","author":"SW Robinson","year":"2014","unstructured":"Robinson SW, Brantley K, Liow C, Teagarden JR. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans. J Manag Care Spec Pharm. 2014 Oct;20(10):997\u20131004.","journal-title":"J Manag Care Spec Pharm"},{"issue":"18","key":"1943_CR37","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med."},{"key":"1943_CR38","unstructured":"Genetics Home Reference, U.S. National Library of Medicine. Spinal muscular atrophy [Internet]. Genetics Home Reference. [cited 2019 Feb 7]. https:\/\/ghr.nlm.nih.gov\/condition\/spinal-muscular-atrophy"},{"key":"1943_CR39","unstructured":"Genetics Home Reference, U.S. National Library of Medicine. Metachromatic leukodystrophy [Internet]. Genetics Home Reference. [cited 2019 Feb 7]. https:\/\/ghr.nlm.nih.gov\/condition\/metachromatic-leukodystrophy"},{"issue":"3","key":"1943_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejpn.2019.03.004","volume":"23","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt E, Edstr\u00f6m J, Sejersen T, Tulinius M, Lochm\u00fcller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: a systematic review. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2019 May;23(3):347\u201356.","journal-title":"Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc"},{"issue":"13","key":"1943_CR41","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1177\/0883073816656401","volume":"31","author":"FS Eichler","year":"2016","unstructured":"Eichler FS, Cox TM, Crombez E, Dali C\u00cd, Kohlsch\u00fctter A. Metachromatic leukodystrophy: an assessment of disease burden. J Child Neurol. 2016;31(13):1457\u201363.","journal-title":"J Child Neurol"},{"key":"1943_CR42","unstructured":"Office of the Commissioner. Press Announcements - FDA approves first drug for spinal muscular atrophy. 2016 Dec 23 [cited 2019 Feb 7]. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm534611.htm"},{"key":"1943_CR43","unstructured":"Metachromatic Leukodystrophy [Internet]. National Organization for Rare Disorders; 2003 [cited 2019 Mar 4]. (Rare Disease Database). https:\/\/rarediseases.org\/rare-diseases\/metachromatic-leukodystrophy\/"},{"key":"1943_CR44","volume-title":"The discovery of grounded theory: strategies for qualitative research","author":"BG Glaser","year":"1967","unstructured":"Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. Hawthorne, N.Y.: Aldine de Gruyter; 1967."},{"key":"1943_CR45","doi-asserted-by":"crossref","unstructured":"Birks M, Mills J. Grounded Theory: A Practical Guide. SAGE; 2015. 209 p.","DOI":"10.4135\/9781473920163.n7"},{"key":"1943_CR46","doi-asserted-by":"crossref","unstructured":"Chun Tie Y, Birks M, Francis K. Grounded theory research: A design framework for novice researchers. SAGE Open Med [Internet]. 2019 Jan 2 [cited 2021 Mar 3];7. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6318722\/","DOI":"10.1177\/2050312118822927"},{"issue":"4","key":"1943_CR47","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1046\/j.1365-2648.1997.00371.x","volume":"26","author":"J Faugier","year":"1997","unstructured":"Faugier J, Sargeant M. Sampling hard to reach populations. J Adv Nurs. 1997 Oct;26(4):790\u20137.","journal-title":"J Adv Nurs"},{"key":"1943_CR48","first-page":"1998","volume-title":"Basics of qualitative research : techniques and procedures for developing grounded theory","author":"AL Strauss","year":"1998","unstructured":"Strauss AL, Corbin JM. Basics of qualitative research\u202f: techniques and procedures for developing grounded theory. Thousand Oaks: Sage Publications; 1998. p. 1998."},{"key":"1943_CR49","doi-asserted-by":"publisher","unstructured":"How Many Interviews Are Enough?: An Experiment with Data Saturation and Variability - Greg Guest, Arwen Bunce, Laura Johnson, 2006 [Internet]. [cited 2019 Apr 30]. https:\/\/journals.sagepub.com\/doi\/abs\/https:\/\/doi.org\/10.1177\/1525822X05279903","DOI":"10.1177\/1525822X05279903"},{"key":"1943_CR50","unstructured":"UN Committee on Economic, Social and Cultural Rights (CESCR). General Comment No. 14: The Right to the Highest Attainable Standard of Health (Art. 12 of the Covenant) [Internet]. 2000 Aug [cited 2020 Jul 14]. https:\/\/www.refworld.org\/docid\/4538838d0.html"},{"issue":"6","key":"1943_CR51","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/jgc4.1161","volume":"28","author":"CM Reuter","year":"2019","unstructured":"Reuter CM, Kohler JN, Bonner D, Zastrow D, Fernandez L, Dries A, et al. Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing. J Genet Couns. 2019 Dec;28(6):1107\u201318.","journal-title":"J Genet Couns"},{"issue":"2","key":"1943_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.pec.2017.08.017","volume":"101","author":"KJ Wells","year":"2018","unstructured":"Wells KJ, Valverde P, Ustjanauskas AE, Calhoun EA, Risendal BC. What are patient navigators doing, for whom, and where? A national survey evaluating the types of services provided by patient navigators. Patient Educ Couns. 2018 Feb;101(2):285\u201394.","journal-title":"Patient Educ Couns"},{"issue":"2","key":"1943_CR53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/hsw\/hlt003","volume":"38","author":"JS Darnell","year":"2013","unstructured":"Darnell JS. Navigators and assisters: two case management roles for social workers in the Affordable Care Act. Health Soc Work. 2013 May;38(2):123\u20136.","journal-title":"Health Soc Work"},{"issue":"15 Suppl","key":"1943_CR54","first-page":"3543","volume":"117","author":"A Natale-Pereira","year":"2011","unstructured":"Natale-Pereira A, Enard KR, Nevarez L, Jones LA. The role of patient navigators in eliminating health disparities. Cancer. 2011 Aug;117(15 Suppl):3543\u201352.","journal-title":"Cancer"},{"issue":"2","key":"1943_CR55","doi-asserted-by":"publisher","first-page":"0191980","DOI":"10.1371\/journal.pone.0191980","volume":"13","author":"KA McBrien","year":"2018","unstructured":"McBrien KA, Ivers N, Barnieh L, Bailey JJ, Lorenzetti DL, Nicholas D, et al. Patient navigators for people with chronic disease: A systematic review. PloS One. 2018;13(2):0191980.","journal-title":"PloS One."},{"issue":"2","key":"1943_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41390-020-01151-5","volume":"89","author":"YS Fraiman","year":"2021","unstructured":"Fraiman YS, Wojcik MH. The influence of social determinants of health on the genetic diagnostic odyssey: who remains undiagnosed, why, and to what effect? Pediatr Res. 2021 Jan;89(2):295\u2013300.","journal-title":"Pediatr Res"},{"issue":"S4","key":"1943_CR57","doi-asserted-by":"publisher","first-page":"S517","DOI":"10.2105\/AJPH.2014.302200","volume":"104","author":"M Marmot","year":"2014","unstructured":"Marmot M, Allen JJ. Social determinants of health equity. Am J Public Health. 2014 Aug 6;104(S4):S517\u20139.","journal-title":"Am J Public Health"},{"issue":"1","key":"1943_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3322\/caac.21586","volume":"70","author":"KI Alcaraz","year":"2020","unstructured":"Alcaraz KI, Wiedt TL, Daniels EC, Yabroff KR, Guerra CE, Wender RC. Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy. CA Cancer J Clin. 2020 Jan;70(1):31\u201346.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1943_CR59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1353\/hcr.2006.0058","volume":"36","author":"N Daniels","year":"2006","unstructured":"Daniels N. Equity and population health: toward a broader bioethics agenda. Hastings Cent Rep. 2006 Aug;36(4):22\u201335.","journal-title":"Hastings Cent Rep"},{"issue":"4","key":"1943_CR60","first-page":"215","volume":"128","author":"N Daniels","year":"1999","unstructured":"Daniels N, Kennedy BP, Kawachi I. Why justice is good for our health: the social determinants of health inequalities. Daedalus. 1999;128(4):215\u201351.","journal-title":"Daedalus"},{"issue":"7","key":"1943_CR61","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","volume":"119","author":"A Angelis","year":"2015","unstructured":"Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy Amst Neth. 2015 Jul;119(7):964\u201379.","journal-title":"Health Policy Amst Neth"},{"key":"1943_CR62","doi-asserted-by":"crossref","unstructured":"Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J. The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs. PLoS ONE [Internet]. 2012 Feb 21;7(2). http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3283698\/","DOI":"10.1371\/journal.pone.0031894"},{"issue":"1","key":"1943_CR63","first-page":"15","volume":"3","author":"R Hyde","year":"2010","unstructured":"Hyde R, Dobrovolny D. Orphan drug pricing and payer management in the United States: Are we approaching the tipping point? Am Health Drug Benefits. 2010;3(1):15\u201323.","journal-title":"Am Health Drug Benefits"},{"issue":"2","key":"1943_CR64","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10551-009-0259-x","volume":"94","author":"TA Hemphill","year":"2010","unstructured":"Hemphill TA. Extraordinary pricing of orphan drugs: is it a socially responsible strategy for the US pharmaceutical industry? J Bus Ethics. 2010;94(2):225\u201342.","journal-title":"J Bus Ethics."},{"issue":"2","key":"1943_CR65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21443","volume":"68","author":"PM Carrera","year":"2018","unstructured":"Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153\u201365.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1943_CR66","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/archpedi.160.2.178","volume":"160","author":"ST Callahan","year":"2006","unstructured":"Callahan ST, Cooper WO. Access to health care for young adults with disabling chronic conditions. Arch Pediatr Adolesc Med. 2006 Feb;160(2):178\u201382.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"1943_CR67","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7326\/0003-4819-149-3-200808050-00006","volume":"149","author":"AP Wilper","year":"2008","unstructured":"Wilper AP, Woolhandler S, Lasser KE, McCormick D, Bor DH, Himmelstein DU. A national study of chronic disease prevalence and access to care in uninsured US adults. Ann Intern Med. 2008;149(3):170\u20136.","journal-title":"Ann Intern Med."},{"issue":"10","key":"1943_CR68","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1056\/NEJMhpr0706165","volume":"358","author":"T Bodenheimer","year":"2008","unstructured":"Bodenheimer T. Coordinating care\u2013a perilous journey through the health care system. N Engl J Med. 2008 Mar 6;358(10):1064\u201371.","journal-title":"N Engl J Med"},{"issue":"2","key":"1943_CR69","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1353\/hpu.2017.0066","volume":"28","author":"C Gunn","year":"2017","unstructured":"Gunn C, Battaglia TA, Parker VA, Clark JA, Paskett ED, Calhoun E, et al. What makes patient navigation most effective: defining useful tasks and networks. J Health Care Poor Underserved. 2017;28(2):663\u201376.","journal-title":"J Health Care Poor Underserved"},{"issue":"6","key":"1943_CR70","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamaoncol.2016.6307","volume":"3","author":"GB Rocque","year":"2017","unstructured":"Rocque GB, Pisu M, Jackson BE, Kvale EA, Demark-Wahnefried W, Martin MY, et al. Resource use and medicare costs during lay navigation for geriatric patients with cancer. JAMA Oncol. 2017;3(6):817\u201325.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1943_CR71","first-page":"1303","volume":"20","author":"ACMG Board of Directors","year":"2018","unstructured":"ACMG Board of Directors. Insuring patient access and affordability for treatments for rare and ultrarare diseases: a policy statement of the American College of Medical Genetics and Genomics. Genet Med Off J Am Coll Med Genet. 2018;20(11):1303\u20134.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"4","key":"1943_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5582\/irdr.2018.01085","volume":"7","author":"N Khosla","year":"2018","unstructured":"Khosla N, Valdez R. A compilation of national plans, policies and government actions for rare diseases in 23 countries. Intractable Rare Dis Res. 2018;7(4):213\u201322.","journal-title":"Intractable Rare Dis Res"},{"key":"1943_CR73","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/978-3-319-67144-4_32","volume":"1031","author":"R Castro","year":"2017","unstructured":"Castro R, Senecat J, de Chalendar M, Vajda I, Dan D, Boncz B, et al. Bridging the Gap between Health and Social Care for Rare Diseases: Key Issues and Innovative Solutions. Adv Exp Med Biol. 2017;1031:605\u201327.","journal-title":"Adv Exp Med Biol"},{"key":"1943_CR74","unstructured":"Project RDAC - Overview [Internet]. NORD (National Organization for Rare Disorders). [cited 2021 Mar 10]. https:\/\/rarediseases.org\/rdac-overview\/"},{"key":"1943_CR75","unstructured":"Rare Disease Caregiving | The National Alliance for Caregiving [Internet]. [cited 2021 Mar 7]. https:\/\/www.caregiving.org\/rare\/"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01943-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01943-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01943-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T05:55:19Z","timestamp":1672811719000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01943-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01943-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-133652\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"assertion":[{"value":"16 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and received IRB approval through the University of Massachusetts Amherst, protocol ID 2018\u20134897.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent to publish deidentified data was received from all participants who participated in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"313"}}